Drug Type Small molecule drug |
Synonyms L-OP, L-Ornithine phenylacetate, OP + [9] |
Target |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), NOS2 modulators(Nitric oxide synthase, inducible modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC13H20N2O4 |
InChIKeyLRSYFEZBIMVWRY-VWMHFEHESA-N |
CAS Registry952154-79-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09942 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 3 | - | 01 Nov 2021 | |
Fibrosis | Phase 3 | - | 01 Nov 2021 | |
Hepatic Encephalopathy | Phase 3 | - | 01 Nov 2021 | |
Hepatic Encephalopathy | Phase 3 | - | 01 Nov 2021 | |
Hyperammonemia | Phase 3 | - | 01 Nov 2021 | |
Hyperammonemia | Phase 3 | - | 01 Nov 2021 | |
Liver Cirrhosis | Phase 3 | US | 01 Dec 2018 | |
Liver Cirrhosis | Phase 3 | PR | 01 Dec 2018 | |
Chemical and Drug Induced Liver Injury | Phase 3 | US | 01 Jun 2012 | |
Liver Failure, Acute | Phase 3 | US | 01 Jun 2012 |
Phase 2 | 226 | (tybvhddfqd) = fyiabibotv zrcsefqhri (hebsydrmow, 34 - 69) View more | Negative | 01 Dec 2021 | |||
Placebo | (tybvhddfqd) = ymjtuygfow zrcsefqhri (hebsydrmow, 53 - 98) View more | ||||||
Phase 2 | 231 | placebo intravenous infusion (Placebo) | daxlkfhlok(leprlgplfv) = uwjqwlrsnn kwwvywxkam (hvuublesie, pqgfjtjomp - vomnrjzdwk) View more | - | 16 Sep 2021 | ||
(Ornithine Phenylacetate) | daxlkfhlok(leprlgplfv) = ubfrqvxdwy kwwvywxkam (hvuublesie, njjizipyre - zjulaxyphq) View more | ||||||
Phase 2 | 50 | (Group A: MNK6106 2 Grams (Tid)) | ciuvavqjep(fjjzvkhsdi) = aqedkjzrpl cuxvafzuvp (plriwshrps, kxpunyqbde - aldeyrrzlz) View more | - | 20 Jul 2021 | ||
(Group B: MNK6106 4 Grams (Bid)) | ciuvavqjep(fjjzvkhsdi) = nuzkjspeqe cuxvafzuvp (plriwshrps, rxkvsgvywh - vrspnujxtp) View more |